Published online Apr 16, 2015. doi: 10.4253/wjge.v7.i4.346
Peer-review started: September 6, 2014
First decision: November 27, 2014
Revised: December 9, 2014
Accepted: January 9, 2015
Article in press: January 12, 2015
Published online: April 16, 2015
Processing time: 225 Days and 19.2 Hours
Type I gastric neuroendocrine tumors (TI-GNETs) are related to chronic atrophic gastritis with hypergastrinemia and enterochromaffin-like cell hyperplasia. The incidence of TI-GNETs has significantly increased, with the great majority being TI-GNETs. TI-GNETs present as small (< 10 mm) and multiple lesions endoscopically and are generally limited to the mucosa or submucosa. Narrow band imaging and high resolution magnification endoscopy may be helpful for the endoscopic diagnosis of TI-GNETs. TI-GNETs are usually histologically classified by World Health Organization criteria as G1 tumors. Therefore, TI-GNETs tend to display nearly benign behavior with a low risk of progression or metastasis. Several treatment options are currently available for these tumors, including surgical resection, endoscopic resection, and endoscopic surveillance. However, debate persists about the best management technique for TI-GNETs.
Core tip: The incidence of type I gastric neuroendocrine tumors (TI-GNETs) has significantly increased, TI-GNETs are the most frequently diagnosed of all GNETs, accounting for about 70%-80%. Endoscopically, TI-GNETs are present as small (< 10 mm), polypoid lesions or, more frequently, as smooth, rounded submucosal lesions. Especially, narrow band imaging and high resolution magnification endoscopy may be helpful for the endoscopic diagnosis of TI-GNETs. TI-GNETs tend to display a nearly benign behavior and a low risk of progression or metastasis in spite of submucosal invasion. Therefore, endoscopic submucosal dissection is a feasible technique for the removal of TI-GNETs.